Neuroblastoma, the most common extracranial solid tumor in children, accounts for nearly 8% of childhood cancers in the United States. It is a disease with pronounced clinical and biological heterogeneities. The amplification of MYCN, whose key tumorigenic functions include the promotion of proliferation, facilitation of the cell's entry into the S phase, and prevention of cells from leaving the cell cycle, correlates with poor prognosis. Patients with a high proliferation index disease have low survival rates. Neuroblastoma is one of the most radioresponsive of all human tumors. To exploit this radiosensitivity, radioactive guanidine (R)-(-)-5-[125 I]iodo-3'-O-[2-(ε-guanidinohexanoyl)-2-phenylacetyl]-2'-deoxyuridine (9, GPAID) was designed. This compound enters neuroblastoma cells much like metaiodobenzylguanidine (MIBG). Additionally, it cotargets DNA of proliferating cells, an attribute especially advantageous in the treatment of MYCN-amplified tumors. GPAID was synthesized from the trimethylstannyl precursor with an average yield of &gt;90% at the no-carrier-added specific activities. The norepinephrine transporter-aided delivery of GPAID to neuroblastoma cells was established in the competitive uptake studies with nonradioactive MIBG. The intracellular processing and DNA targeting properties were confirmed in the subcellular distribution experiments. Studies in a mouse model of neuroblastoma demonstrated the therapeutic potential of GPAID. The tin precursor of GPAID can be used to prepare compounds radiolabeled with single-photon emission computed tomography (SPECT)- and positron-emission tomography (PET)-compatible radionuclides. Accordingly, these reagents can function as theranostics useful in the individualized and comprehensive treatment strategies comprising treatment planning and the assessment of tumor responses as well as the targeted molecular radiotherapy employing treatment doses derived from the imaging data. © 2020 John Wiley &amp; Sons, Ltd.OBJECTIVES Kranioti, Grigorescu, and Harvati have recently described (PLoS One 2019, 14(7),e0216718) the breakage to the Cioclovina 1 earlier Upper Paleolithic cranium as indicating fatal interhuman blunt trauma. We have reassessed their analysis in terms of the specimen's condition at discovery, its current condition, and the post-discovery history of the cranium. MATERIALS AND METHODS The original Cioclovina 1 neurocranium and currently associated pieces were visually assessed for the nature of the damage to them, and the records of its discovery, the original 1942 photographs, and their subsequent history in Bucharest were reviewed. RESULTS The damage to Cioclovina 1, attributed by Kranioti and colleagues to perimortem blunt trauma, was not present at the time of its 1940-41 discovery in the Peştera Cioclovina Uscată. The "trauma" is from the World War II bombing of the University of Bucharest and subsequent attempts to restore the cranium. https://www.selleckchem.com/products/filgotinib.html The damage does not, and cannot, document interhuman violence in the Pleistocene. CONCLUSIONS Although other cases of antemortem and perimortem trauma are known from the earlier Upper Paleolithic, and Pleistocene humans more broadly, there is absolutely no evidence of perimortem trauma on the Cioclovina 1 cranium. Proper assessment of levels and patterns of human trauma in the Pleistocene must be based on the correct paleontological, taphonomic, and historical assessment of the fossil remains in question. © 2020 Wiley Periodicals, Inc.This paper considers the clustering problem of physical step count data recorded on wearable devices. Clustering step data give an insight into an individual's activity status and further provide the groundwork for health-related policies. However, classical methods, such as K-means clustering and hierarchical clustering, are not suitable for step count data that are typically high-dimensional and zero-inflated. This paper presents a new clustering method for step data based on a novel combination of ensemble clustering and binning. We first construct multiple sets of binned data by changing the size and starting position of the bin, and then merge the clustering results from the binned data using a voting method. The advantage of binning, as a critical component, is that it substantially reduces the dimension of the original data while preserving the essential characteristics of the data. As a result, combining clustering results from multiple binned data can provide an improved clustering result that reflects both local and global structures of the data. Simulation studies and real data analysis were carried out to evaluate the empirical performance of the proposed method and demonstrate its general&nbsp;utility. © 2020 The International Biometric Society.Altered expression of the carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) has been linked to adverse tumor features in various cancer types. To better understand the role of CEACAM1 in prostate cancer, we analyzed a tissue microarray containing tumor spots from 17,747 prostate cancer patients by means of immunohistochemistry. Normal prostate glands showed intense membranous CEACAM1 positivity. Immunostaining was interpretable in 13,625 cancers and was considered high in 28%, low in 43% and absent in 29% of tumors. Low and lost CEACAM1 expression was strongly linked to adverse tumor features including high classical and quantitative Gleason grade, lymph node metastasis, advanced tumor stage, positive surgical margin, a high number of genomic deletions and early biochemical recurrence (p? less then ?0.0001 each). Subset analysis of molecularly defined cancer subsets revealed that these associations were strongest in V-ets avian erythroblastosis virus E26 oncogene homolog (ERG) fusion-positive cancers and that CEACAM1 loss was prognostic even in tumors harboring genomic deletions of the phosphatase and tensin homolog tumor suppressor (p? less then ?0.0001). Multivariate analysis suggested that CEACAM1 analysis can provide independent prognostic information beyond established prognosis parameters at the stage of the initial biopsy when therapy decisions must be taken. In conclusion, loss of CEACAM1 expression predicts poor prognosis in prostate cancer and might provide clinically useful prognostic information particularly in cancers harboring the TMPRSS2ERG fusion. © 2020 The Authors. International Journal of Cancer published by John Wiley &amp; Sons Ltd on behalf of UICC.